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Purpose: Single nucleotide polymorphisms (SNPs) in the LOXL1 gene have been implicated in exfoliation syndrome
(XFS) and exfoliation glaucoma (XFG). We have shown that these SNPs are not associated with the primary glaucomas
such as primary open-angle (POAG) glaucoma and primary angle-closure glaucoma (PACG). To further establish the
specificity of LOXL1 SNPs for XFS and XFG, we determined whether these SNPs were involved in pigment dispersion
syndrome (PDS) and pigmentary glaucoma (PG).
Methods: Three SNPs of LOXL1 (rs1048661, rs3825942, and rs2165241) were screened in a cohort of 78 unrelated and
clinically well characterized glaucoma cases comprising of PG (n=44) and PDS (n=34) patients as well as 108 ethnically
matched  normal  controls  of  Caucasian  origin.  The  criteria  for  diagnosis  of  PDS/PG  were  Krukenberg  spindle,
hyperpigmentation of the trabecular meshwork, and wide open angle. Transillumination defects were detected by infrared
pupillography, and the presence of a Zentmayer ring was considered as a confirmatory sign. All three SNPs were genotyped
in cases and controls by resequencing the genomic region of LOXL1 harboring these variants and were further confirmed
by polymerase chain reaction (PCR)-based restriction digestions. Haplotypes were generated from the genotype data, and
the linkage disequilibrium (LD) and haplotype analysis were done with Haploview software that uses the expectation
maximization (EM) algorithm.
Results: The LOXL1 SNPs showed no significant association with PDS or PG. There was no significant difference in the
frequencies of the risk alleles of rs1048661 (‘G’ allele; p=0.309), rs3825942 (‘G’ allele’ p=0.461), and rs2165241 (‘T’
allele; p=0.432) between PG/PDS cases and controls. Similarly, there was no involvement of the XFS/XFG-associated
haplotypes, ‘G-G’ (p=0.643; [OR=1.08, 95%CI, 0.59–1.97]) and ‘T-G’ (p=0.266; [OR=1.35, 95%CI, 0.70–2.60]), with
the PDS/PG phenotypes. The risk haplotype ‘G-G’ was observed in ~55% of the normal controls.
Conclusions: There was no involvement of the LOXL1 SNPs in patients with PDS and PG. The results further indicate
that the associations of these SNPs are specific to XFS/XFG.
Glaucoma is a chronic, progressive neurodegenerative
disorder characterized by a specific pattern of optic nerve head
and visual field damage, which represents the final common
pathway of a heterogeneous group of entities that affect the
eye  [1,2].  It  is  the  second  leading  cause  of  irreversible
blindness worldwide, and it has been estimated that it will
affect approximately 80 million people by the year 2020 [3].
Exfoliation  syndrome  (XFS)  is  an  age-related,
generalized disorder of the extracellular matrix characterized
by the production and progressive accumulation of a fibrillar
extracellular material in many ocular tissues and is the most
common  identifiable  cause  of  open-angle  glaucoma
worldwide  [4].  It  plays  an  etiologic  role  in  open-angle
glaucoma, angle-closure glaucoma, cataract, and retinal vein
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occlusion and has been associated with an increasing number
of systemic disorders including vascular disease, hearing loss,
and Alzheimer disease [5-8]. Exfoliation syndrome appears
to be a disease of elastic tissue microfibrils.
Recently, single nucleotide polymorphisms (SNPs) in the
LOXL1  gene  (OMIM  153456)  at  15q24.1  have  been
implicated in exfoliation syndrome and exfoliation glaucoma
(XFG) [9]. Two non-synonymous SNPs in exon 1 of LOXL1
(rs1048661  [R141L]  and  rs3825942  [G135D])  were
demonstrated to exhibit a strong association with XFS and
XFG in an Icelandic and Swedish population [9] that was later
replicated across multiple populations worldwide [10-19]. It
was also shown that LOXL1 SNPs are not associated with
primary glaucomas [20,21].
Pigment dispersion syndrome (PDS; OMIM 600510) and
pigmentary glaucoma (PG) are characterized by a disruption
of the iris pigment epithelium (IPE) and deposition of the
dispersed pigment granules throughout the anterior segment
[22].  The  classic  diagnostic  triad  consists  of  corneal
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1254pigmentation  (Krukenberg  spindle);  slit-like,  radial,  mid-
peripheral iris transillumination defects; and dense trabecular
pigmentation [23]. The iris insertion is typically posterior, and
the peripheral iris tends to bow posteriorly [24]. About 80%
of patients with PDS are myopes and 20% are emmetropes.
The basic abnormality in this hereditary disorder remains
unknown.
The  frequency  with  which  PDS  converts  to  PG  has
probably been greatly overestimated. The three studies that
have examined patients longitudinally suggest that up to 50%
will eventually develop glaucoma [25-27]. However, the true
rate of PDS in the general population may be an order of
magnitude greater than has previously been suspected [28]. In
a retrospective community-based study, 113 patients of whom
nine developed PG or elevated intraocular pressure (IOP) that
required therapy were newly diagnosed with PDS over 24
years [29]. The probability of converting to PG was 10% at
five years and 15% at 15 years.
PDS/PG  is  an  autosomal  dominant  disorder  and  was
mapped  to  the  7q35-q36  locus  by  linkage  analysis  [30],
although the candidate gene is yet to be identified. While
POAG shares several clinical features with PDS, there was no
evidence of linkage to the POAG-associated 1q21-q31 locus
in PDS, indicating that there would be other candidate loci
that are yet uncharacterized [31,32].
XFS and PDS are two common disorders that can produce
secondary glaucoma through trabecular blockage [22,33]. To
further establish the specificity of this association, we studied
the  involvement  of  the  three  XFS-  and  XFG-associated
LOXL1 SNPs in a cohort of Caucasian PDS and PG patients
from New York.
METHODS
Clinical details of the subjects: The study protocol adhered to
the tenets of the Declaration of Helsinki and was approved by
the Institutional Review Boards of the New York Eye and Ear
Infirmary (NYEE) and the L.V. Prasad Eye Institute. The
cohort comprised 78 unrelated patients with PG (n=44) and
PDS (n=34) seen at the NYEE between 1998 and 2003 along
with 108 normal controls. The diagnoses of PDS/PG were
independently  confirmed  by  two  surgeons  based  on  the
inclusion and exclusion criteria mentioned earlier [33]. The
criteria  for  diagnosis  of  PDS  required  the  presence  of
Krukenberg spindles, a deep anterior chamber, wide open
angles  on  gonioscopy,  and  hyperpigmented  trabecular
meshwork.  Transillumination  defects  were  detected  by
infrared pupillography. A Zentmayer ring was considered to
Figure  1.  Genotype  pattern  of  the
LOXL1 SNP rs1048661 (R141L). The
representative electropherograms show
the  three  genotype  patterns  for  the
rs1048661  (G>T)  SNP  in  A  (TT;
homozygous),  B  (GT;  heterozygous),
and C (GG; wild type). The arrow heads
indicate the point of substitution. The
normal  sequence  is  provided  in  the
upper  panel  above  each
electropherogram. D demonstrates the
confirmation of these variants by PCR-
based  restriction  digestion  in  a  non-
denaturing  polyacrylamide  gel.  The
PCR  amplicon  (464  bp)  for  LOXL1
(obtained using the primer pairs 5′-GCA
GGT GTA CAG CTT GCT CA-3′ and
5′-ACA  CGA  AAC  CCT  GGT  CGT
AG-3′)  after  digestion  with  SmaI
cleaved into fragments of 201 bp, 189
bp, and 74 bp in the wild type (lane 4).
Presence of the variant abolished the site
for this restriction enzyme, generating
an intact fragment of 390 bp and 74 bp
in the individual homozygous for this
variant (lane 2). The individual with the
heterozygous variant (lane 3) exhibits
all the fragments (390 bp, 210 bp, 189
bp, and 74 bp). Lane 1 contains the 100
bp  DNA  ladder  (Gene  RulerTM;  MBI
Fermentas, Vilnius, Lithuania).
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1255be confirmatory. A pigment reversal sign was only considered
as a soft sign and not categorized as PDS. A diagnosis of PG
required PDS plus typical glaucomatous optic disc and visual
field damage.
Normal adult individuals without any signs or symptoms
of glaucoma and other systemic diseases served as controls.
Their visual acuity ranged from 20/20 to 20/40, and their IOP
was less than 21 mmHg. The stereodisc exam did not reveal
any changes in the optic disc suggestive of glaucoma. All the
subjects underwent visual field testing with the Humphreys
visual field analyzer (Carl Zeiss Meditec, Dublin, CA). This
was essentially a diagnosis of exclusion: normal pattern of
neuroretinal rim, absence of notching or thinning of the rim,
and disc hemorrhage or nerve fiber layer defects. The cup/disc
ratio related to the disc size, the asymmetry of cup to disc ratio
less than or equal to 0.2:1 (corrected for size), and the absence
of a beta zone peripapillary atrophy were “soft” signs. All the
patients  and  controls  were  matched  with  respect  to  their
ethnicity.
Molecular analysis: Peripheral blood samples (5–10 ml) were
collected  from  each  subject  by  venipuncture  with  prior
informed  consent,  and  DNA  was  extracted  by  standard
protocols [34]. The three SNPs in exon 1 (rs1048661 and
rs3825942)  and  intron  1  (rs2165241)  of  LOXL1  were
amplified  with  pre-designed  primers;  the  amplicons  were
purified  and  screened  by  re-sequencing  using  BigDye
chemistry  (version  3.1)  on  an  ABI  3100  DNA  Analyzer
(Applied Biosystems, Foster City, CA) as described earlier
[21]. The genotypes of a subset of patients and controls were
further confirmed by restriction digestion of the amplicons at
37  °C  overnight  with  appropriate  restriction  enzymes  as
detailed  earlier  [21].  The  genotyping  was  repeated
independently  by  investigators  who  were  masked  to  the
phenotypes. Representative chromatograms displaying all the
genotype patterns for these three SNPs are provided in Figure
1  (rs1048661),  Figure  2  (rs3825942),  and  Figure  3
(rs2165241).
Statistical analysis: The maximum likelihood estimates of
allele  frequencies,  Hardy–Weinberg  equilibrium,  and
haplotype frequencies were estimated from the genotype data
at the three SNP loci using Haploview software that uses the
expectation  maximization  (EM)  algorithm  [35].  Pairwise
linkage disequilibrium (LD) between the individual SNPs was
calculated using the LD-plot function of this software.  χ2
analysis was done to assess the significance between the allele
frequencies. The odds ratios were calculated to assess the risk
of the individual alleles of all three SNPs.
Figure  2.  Genotype  pattern  of  the
LOXL1  SNP  rs3825942  (G153D).
Representative electropherograms show
the  three  genotype  patterns  for  the
rs3825942  (G>A)  SNP  in  A  (GA;
heterozygous), B (GG; wild type), and
C (AA; homozygous). The arrow heads
indicate the point of substitution. The
normal  sequence  is  provided  in  the
upper  panel  above  each
electropherogram. D demonstrates the
confirmation of these variants by PCR-
based  restriction  digestion  in  a  non-
denaturing  polyacrylamide  gel.  The
PCR  amplicon  (464  bp)  for  LOXL1
(obtained using the primer pairs 5′-GCA
GGT GTA CAG CTT GCT CA-3′ and
5′-ACA  CGA  AAC  CCT  GGT  CGT
AG-3′)  after  digestion  with  HinfI
generated an intact fragment of 464 bp
in the wild type (lane 3). Presence of the
variation generated a restriction site for
this enzyme and cleaved into fragments
of 311 bp and 153 bp in the individual
homozygous for this change (lane 4).
The  individual  heterozygous  for  this
change  (lane  2)  exhibited  all  three
fragments (464 bp, 311 bp, and 153 bp).
Lane 1 contains the 100 bp DNA ladder
(Gene  RulerTM;  MBI  Fermentas,
Vilnius, Lithuania).
Molecular Vision 2008; 14:1254-1262 <http://www.molvis.org/molvis/v14/a148> © 2008 Molecular Vision
1256RESULTS
Distribution of the LOXL1 single nucleotide polymorphisms
in pigment dispersion syndrome and pigmentary glaucoma:
The  study  cohort  conformed  to  the  Hardy–Weinberg
equilibrium. The allele frequencies of the three SNPs and their
corresponding allele counts are provided in Table 1. There
was no significant difference in the frequencies of the XFS/
XFG-associated alleles among the PG and PDS patients and
controls. The allele frequencies were consistent even after
categorizing the data set into PG and PDS phenotypes (Table
1).  Similarly,  there  were  no  differences  in  the  genotype
frequencies of these alleles across these three LOXL1 SNPs in
PG and PDS cohorts (data not shown).
Figure  3.  Genotype  pattern  of  the
intronic  LOXL1  SNP  rs2165241.
Representative electropherograms show
the  three  genotype  patterns  for  the
rs2165241 (C>T) SNP in A (CC; wild
type), B (TT; homozygous), and C (CT;
heterozygous).  The  arrow  heads
indicate the point of substitution. The
normal  sequence  is  provided  in  the
upper  panel  above  each
electropherogram. D demonstrates the
confirmation of these variants by PCR-
based  restriction  digestion  in  a  non-
denaturing  polyacrylamide  gel.  The
PCR  amplicon  (264  bp)  for  LOXL1
(obtained using the primer pairs 5′-TAG
GGC CCC TTG GAG AAT AG-3′ and
5′-GTC  CCA  TTC  CCC  TCT  CAA
TC-3′)  after  digestion  with  SspI
generated an intact fragment of 264 bp
in the wild type (lane 1). Presence of the
variation generated a restriction site for
this enzyme and cleaved into fragments
of 147 bp and 117 bp in the individual
homozygous for this change (lane 2).
The  individual  heterozygous  for  this
change  (lane  3)  exhibited  all  three
fragments (264 bp, 147 bp, and 117 bp).
Lane  4  contains  an  undigested
amplicon, and Lane 5 contains the 100
bp  DNA  ladder  (Gene  RulerTM;  MBI
Fermentas, Vilnius, Lithuania).
TABLE 1. ALLELE FREQUENCY DISTRIBUTIONS ACROSS PG/PDS CASES AND CONTROLS FOR THE THREE LOXL1 SNPS.
SNPs (Allele) Phenotypes
Allele frequency (Counts)
p value Cases Controls
rs1048661
(G)
PG+PDS 0.674 (97/47) 0.724 (152/58) 0.309
PG 0.679 (57/27) 0.734 (152/58) 0.439
PDS 0.667 (40/20) 0.724 (152/58) 0.389
rs3825942
(G)
PG+PDS 0.852 (121/21) 0.822 (176/38) 0.461
PG 0.866 (71/11) 0.822 (176/38) 0.368
PDS 0.833 (50/10) 0.822 (176/38) 0.844
rs2165241
(T)
PG+PDS 0.514 (74/70) 0.471 (99/111) 0.432
PG 0.524 (44/40) 0.471 (99/111) 0.417
PDS 0.500 (30/30) 0.471 (99/111) 0.91
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1257Haplotype  analysis  of  the  LOXL1  single  nucleotide
polymorphisms: Haplotypes were generated with the three
LOXL1 intragenic SNPs among PG/PDS cases and controls.
There  was  a  strong  pairwise  linkage  disequilibrium  (LD)
between  the  rs1048661  and  rs3825942  (D’=0.89,  95%CI,
0.57–0.97) SNPs and between the rs3825942 and rs2165241
(D’=1.00, 95%CI, 0.81–1.00) SNPs, similar to earlier studies
[11-15,17-20].
Four  different  haplotypes  could  be  generated  (with
frequency greater than 5%) with these three SNPs in PG/PDS
patients and controls. There were no significant differences in
the haplotype frequencies between the cases and controls.
These results were consistent even after reanalysis of the
haplotype data with respect to PG and PDS phenotypes and
controls (Table 2).
DISCUSSION
XFS is the most common identifiable cause of open-angle
glaucoma worldwide. It is also associated with extra-ocular
abnormalities [36,37]. Recently, intragenic SNPs in LOXL1
were implicated in XFS and XFG in an Icelandic and Swedish
population [9]. Several studies conducted on XFS and XFG
worldwide were able to independently replicate these findings
in  geographically  and  ethnically  diverse  cohorts  [10-19].
Since LOXL1 SNPs were implicated in a secondary glaucoma,
we  analyzed  these  variations  in  PDS/PG  to  establish  the
uniqueness of this association. To the best of our knowledge,
this is the first report to screen for these SNPs in PG/PDS.
The data from the present study show that the three XFS/
XFG-associated SNPs were not involved with PG or PDS. The
significant associations of the rs1048661 (G allele) and the
rs3825942 (G allele) SNPs have been consistent to XFS and
XFG  across  multiple  populations  worldwide  except  in
Japanese  (Table  3).  On  the  contrary,  the  “T”  allele
(rs1048661)  has  exhibited  strong  association  with  the
Japanese XFS/XFG patients [16,19]. So far, these SNPs have
not  been  involved  with  primary  glaucomas  [9,12,20,21].
However, the allele frequencies of the LOXL1 SNPs in PG/
PDS  patients  were  similar  to  that  observed  in  primary
glaucomas (Table 3).
There was no significant association with the LOXL1
haplotypes  either  with  PG  or  PDS  (Table  2).  Since  most
studies had demonstrated a significant risk with haplotypes
generated with the rs1048661 and rs3825942 SNPs [9-15,
17-19],  a  similar  exercise  was  conducted  to  draw  a
comparison of the haplotype structure in the present cohort
with other studies. The frequency of the risk haplotype with
these  two  SNPs  (G-G)  was  observed  in  lower  frequency
among the PG/PDS patients compared to other studies; this
risk haplotype was also present in ~55% of the control subjects
(Table 4). Unlike previous studies on XFS and XFG, there
was no risk associated with the G-G (OR=1.08, 95%CI, 0.59–
1.97) and T-G (OR=1.35, 95%CI, 0.70–2.60) haplotypes in
PG/PDS (Table 4).
While PG/PDS occurs relatively early in life, XFS/XFG
occurs at a later stage. It has been suggested that certain PDS
patients who do not achieve IOP control could later progress
to develop XFS/XFG [38]. Based on this, the concept of an
“overlap”  syndrome  has  been  suggested  whereby  the
sequential appearance of two or more risk factors lead to
glaucomatous damage [33].
In summary, we aimed to determine if the LOXL1 SNPs
associated  with  XFS/XFG  were  involved  in  another
secondary glaucoma. The high population attributable risks
for  the  high-risk  haplotype  among  the  diverse  XFS/XFG
patients strongly suggest that these variants are exclusive to
XFS and XFG [9,13]. The non-association of the LOXL1
SNPs in our PG/PDS cohort further supports the fact that these
are  XFS-specific  and  may  not  be  involved  with  other
secondary  glaucomas.  Although  PG/PDS  share  certain
discrete clinical features with XFS, their underlying molecular
mechanisms remain to be elucidated.
TABLE 2. ESTIMATED LOXL1 HAPLOTYPE FREQUENCIES OF PG/PDS PATIENTS AND CONTROLS.
Haplotypes Phenotypes % Cases % Controls p value
G-G-T PG+PDS 46.6 45.8 0.881
PG 48 45.8 0.729
PDS 44.9 45.9 0.883
T-G-C PG+PDS 27.9 24.8 0.511
PG 27.1 24.8 0.683
PDS 29.1 24.9 0.495
G-A-C PG+PDS 13.8 16.8 0.451
PG 12.4 16.7 0.364
PDS 15.5 16.6 0.831
G-G-C PG+PDS 7.7 10 0.464
PG 7.4 10 0.483
PDS 8.1 9.9 0.662
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